ATRA - CIK 0001604464
Atara Biotherapeutics, Inc. (ATRA) reported net income of $32.69M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $32.69M | +138.3% |
| FY 2024 | -$85.40M | +69.1% |
| FY 2023 | -$276.13M | -20.9% |
| FY 2022 | -$228.30M | +32.9% |
| FY 2021 | -$340.14M | -10.9% |
| FY 2020 | -$306.62M | -5.4% |
| FY 2019 | -$290.98M | -26.1% |
| FY 2018 | -$230.70M | -93.1% |
| FY 2017 |
Atara Biotherapeutics, Inc. (ATRA) reported net income of $32.69M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, Atara Biotherapeutics, Inc.'s net income grew from -$8.77M to $32.69M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$119.49M |
| -51.2% |
| FY 2016 | -$79.05M | -38.1% |
| FY 2015 | -$57.22M | -104.3% |
| FY 2014 | -$28.01M | -219.2% |
| FY 2013 | -$8.77M | - |